How MDMA Is Transforming Mental Health - Dr Dan Engle | Modern Wisdom Podcast 367

How MDMA Is Transforming Mental Health - Dr Dan Engle | Modern Wisdom Podcast 367

Modern WisdomSep 4, 20211h 32m

Dr. Dan Engle (guest), Chris Williamson (host)

MDMA‑assisted psychotherapy for PTSD and traumaLimitations of conventional psychiatry and pharmaceuticalsA three‑level framework for different psychedelic medicinesNeurobiology of MDMA (oxytocin, amygdala, prefrontal cortex, memory)Complex PTSD, early childhood trauma, and transgenerational traumaSet, setting, facilitation, and integration practicesLegalization, MAPS trials, and the future of transformational medicine

In this episode of Modern Wisdom, featuring Dr. Dan Engle and Chris Williamson, How MDMA Is Transforming Mental Health - Dr Dan Engle | Modern Wisdom Podcast 367 explores mDMA Therapy: A Safe, Powerful Revolution in Treating Deep Trauma Psychiatrist Dr. Dan Engle explains how MDMA‑assisted psychotherapy is transforming mental health by addressing root‑cause trauma rather than just symptom management with traditional pharmaceuticals.

MDMA Therapy: A Safe, Powerful Revolution in Treating Deep Trauma

Psychiatrist Dr. Dan Engle explains how MDMA‑assisted psychotherapy is transforming mental health by addressing root‑cause trauma rather than just symptom management with traditional pharmaceuticals.

He outlines a practical framework of ‘levels’ of psychedelic medicines, emphasizing preparation, self‑regulation, skilled facilitation, and careful contraindications to avoid doing harm.

MDMA’s unique neurochemistry—boosting oxytocin, dampening fear responses, and enhancing memory and self‑witnessing—creates an unusually favorable state for processing PTSD and complex childhood trauma.

Engle stresses that long‑term change depends less on the drug session itself and more on integration, accountability, and supportive community, as psychedelic medicine moves toward legal clinical use.

Key Takeaways

MDMA‑assisted psychotherapy shows unprecedented cure rates for severe PTSD.

MAPS trials report roughly 60–80% of participants with chronic, severe PTSD no longer meeting diagnostic criteria after only two to three MDMA sessions embedded in a 15‑session therapeutic protocol—far surpassing the ~35–40% improvement rates of standard care.

Get the full analysis with uListen AI

The drug session is only a fraction of the work; integration is the majority.

Engle suggests roughly 5–10% of effort is preparation, 30–40% is the medicine experience, and 50–60% is integration—turning insights into new behaviors via accountability, continued therapy, and community support.

Get the full analysis with uListen AI

MDMA creates an optimal neurochemical state for revisiting trauma safely.

By flooding the system with oxytocin, down‑regulating the amygdala (fear center), and enhancing prefrontal ‘witnessing’ and hippocampal memory, MDMA lets people explore painful experiences with less terror and more clarity and compassion.

Get the full analysis with uListen AI

Not all psychedelics are equal; tailor the medicine to the person and goal.

Engle’s ‘Level 0–3’ model distinguishes softer, more navigable medicines like MDMA, ketamine, and low‑dose psilocybin (Level 1) from heavier, riskier processes like ayahuasca/peyote (Level 2) and DMT/iboga (Level 3), which demand more preparation and expert facilitation.

Get the full analysis with uListen AI

Complex PTSD from early or subtle experiences is more common than classic PTSD.

Engle estimates roughly 60–70% of trauma he encounters is ‘complex’—built from early, often pre‑verbal experiences and ongoing erosions of safety (e. ...

Get the full analysis with uListen AI

Skilled facilitation and clear contraindications are critical for safety.

Conditions like heart disease, epilepsy, current psychopharmaceutical use, and histories of psychosis or mania can make MDMA risky; untrained or underground facilitators can also re‑traumatize clients by surfacing material they can’t safely hold or integrate.

Get the full analysis with uListen AI

The coming MDMA ‘renaissance’ will demand new medical and social structures.

With MDMA likely to be legalized for clinical use within 18–24 months, Engle anticipates tens of thousands of therapists and thousands of centers will be needed, plus insurance reform and sustainability ethics for plant medicines as the broader psychedelic field scales.

Get the full analysis with uListen AI

Notable Quotes

For once we have really strategic, pretty consistently successful therapeutics that get down to root cause issues versus treating the symptoms.

Dr. Dan Engle

If you were to construct a neurochemical profile for an agent that’s so good at helping to work with trauma, you’d be hard pressed to find one better than MDMA.

Dr. Dan Engle

The medicines are not here to fix anything. They’re here to show us truth and help support us do our work in order to become more whole humans.

Dr. Dan Engle

I learned more about myself in one weekend with ayahuasca than I had in one decade of psychotherapy.

Dr. Dan Engle

We have this growing privilege to heal… to unburden our children and the coming generations from having to carry our shit.

Dr. Dan Engle

Questions Answered in This Episode

How should someone decide whether MDMA, another psychedelic, or non‑drug therapy is the right next step for their own trauma work?

Psychiatrist Dr. ...

Get the full analysis with uListen AI

What guardrails or standards should be in place to prevent commercialization from diluting safety and ethics as MDMA therapy becomes legal and more common?

He outlines a practical framework of ‘levels’ of psychedelic medicines, emphasizing preparation, self‑regulation, skilled facilitation, and careful contraindications to avoid doing harm.

Get the full analysis with uListen AI

Given the importance of integration, what concrete practices and structures (daily habits, people, environments) most reliably turn a powerful session into lasting life change?

MDMA’s unique neurochemistry—boosting oxytocin, dampening fear responses, and enhancing memory and self‑witnessing—creates an unusually favorable state for processing PTSD and complex childhood trauma.

Get the full analysis with uListen AI

How can societies realistically expand access to MDMA‑assisted psychotherapy for those most in need, given the likely high initial costs and limited number of trained facilitators?

Engle stresses that long‑term change depends less on the drug session itself and more on integration, accountability, and supportive community, as psychedelic medicine moves toward legal clinical use.

Get the full analysis with uListen AI

In what ways might widespread psychedelic therapy reshape our understanding of responsibility, victimhood, and transgenerational trauma at a cultural level?

Get the full analysis with uListen AI

Transcript Preview

Dr. Dan Engle

The most exciting thing in mental health care right now is psychedelic therapies, because for once we have really strategic, pretty consistently successful therapeutics that get down to root cause issues versus treating the symptoms.

Chris Williamson

(wind blowing) Dr. Dan Engel, welcome to the show.

Dr. Dan Engle

Ah, it's good to be with you, Chris. Thanks for having me on, man.

Chris Williamson

I am very, very happy to have you here. How would you describe what you do for work?

Dr. Dan Engle

Uh, these days the conceptual frame of that is transformational medicine, which incorporates a lot of different things and we could dissect that out, but I'd say that's the gist of it.

Chris Williamson

All right. How many MDMA-assisted psychotherapy sessions have you done, like, that you've sat with or facilitated?

Dr. Dan Engle

Oh. On or off the record? (laughs)

Chris Williamson

Uh, well, we're- we're definitely on the record now-

Dr. Dan Engle

(laughs)

Chris Williamson

... um, but you can incl- you can include whatever you want.

Dr. Dan Engle

Yeah. Um, I've facilitated, I don't know now, uh, several hundred different medicine sessions, and I don't know if I've even kept a track of which ones are which different medicines. Um, historically I've facilitated with quite a few different medicines for people in different contexts, sometimes individual, sometimes group, um, sometimes in the States, sometimes out of the States. Um, there's a variety of different contexts where we can do that legally, whether it's in a religious context or if it's in a retreat context in places where medicines are legal and used. Um, I lived down in South America outside of Iquitos, Peru for about a year studying with ayahuasca, uh, in a apprenticeship, and that was 15 years ago when there wasn't much really known or understood or appreciated about ayahuasca. And at that time, I really started to get into the- the curiosity and the- the fascination with how you have different levels of people who can be supportive to another going through a process. You have sitters, you have therapists, i.e. facilitator, facilitators in more of kind of a Western psychological framework, and then you have trackers, you know, trackers that be- that really can pick up the subtle nuances of the landscape and help people rescue those lost parts of themselves.

Chris Williamson

What are your credentials?

Dr. Dan Engle

A medical doctor. You know, I've gone through, um, medical school here in the States, uh, my- so that was in San Antonio where I grew up. Uh, I did my psychiatry residency in Denver, uh, that was three years. Then I did, uh, two psych fellowships, one in forensic psych and one in child psych, and finished that up in Portland. And I've medical- I've been the medical director for, let's see, eight different centers, um, up to now and to the eve of what we were just talking about, launching Kuya in about two weeks.

Chris Williamson

Is it rare for somebody in the plant medicine world to have this degree of Western clinical credentials as well?

Install uListen to search the full transcript and get AI-powered insights

Get Full Transcript

Get more from every podcast

AI summaries, searchable transcripts, and fact-checking. Free forever.

Add to Chrome